Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Frizzo, where did the 10% efficiency min come from? Where are they now?
Thanks!
I asked them, and did not receive a reply.
Maybe if others hit them up too?
Short Interest
4,545 (-95.63%) 05/31/2018
Does this mean that 95% of transactions were short sales?
Ed said the company should reach break even financials by mid year '18. Could be happening!
Have you been there before? Google maps shows a dental office at the address (one year ago)
https://www.google.com/maps/place/711+N+Bell+Blvd+Suite+A,+Cedar+Park,+TX+78613/@30.5175711,-97.8278681,3a,60y,57.01h,88.97t/data=!3m8!1e1!3m6!1sgmf4Llmqu7aM-DnBkl0iEw!2e0!3e11!6s%2F%2Fgeo0.ggpht.com%2Fmaps%2Fphotothumb%2Ffd%2Fv1%3Fbpb%3DChAKDnNlYXJjaC5UQUNUSUxFEk4KQAn91cKrAC1bhhGaAWq0hcoXDxosCxDThbhCGiMaIQoWChQKEgn91cKrAC1bhhGyqRvUk2m9OhIHU3VpdGUgQQwqCg0AAAAAFQAAAAAaBQhqEIgD%26gl%3DUS!7i13312!8i6656!4m5!3m4!1s0x865b2d00abc2d5fd:0xf17ca85b46a019a!8m2!3d30.5173355!4d-97.8283923
or, is that it across the street?
Can you post a screen shot?
Thanks!
Link please!
CBD FROM HEMP OIL VS. CBD FROM MEDICAL MARIJUANA
https://www.medicalmarijuanainc.com/cbd-hemp-oil-vs-cbd-medical-marijuana/
Link please
I don't see MEC anywhere. Is this powered by MEC?
Exactly! Read in context.
Couple has baby using INVOcell, an alternative to IVF
http://wtkr.com/2018/06/03/local-couple-has-baby-using-invocell-an-alternative-to-ivf/
But this wouldn't legalize CBD, would it?
Is there a bill coming up?
That, and that they produced a significant amount of hydrogen!
Dr. Kevin recently met with Dr. Mehmet Oz in China to discuss the challenges of global access to fertility care.
https://www.facebook.com/effortlessivfus/photos/a.2005587739658831.1073741827.1741272319423709/2024540324430239/?type=3&theater
Ed owns like 48% of shares; so he has skin in the company!
Anyone have a feel for how serious these "anomalies" are?
PATSCAN CMR Development Progress
Among our many efforts, the management and engineering teams are focused on developing and honing the PATSCAN CMR antennae system. During the past 3 months (February-April 2018), our engineers invested significant time and effort fine tuning and managing minute background anomalies found in real-world environments that were not readily identifiable in previous laboratory studies. Our PATSCAN CMR hardware team, led by radar expert Dr. Paul Rice, has instituted an antenna update program, which includes additional testing at our Las Vegas development center.
We are justifiably pleased that our work with the Westgate Las Vegas Casino & Resort has provided in-depth and practical field study results at this key juncture. We have saved significant capital and amassed strategically important data that we would not have otherwise collected as quickly. Given that our product, when released commercially, will play a front-line defensive role in potential life and death situations, there is a fundamental need to ensure the technology works effectively. There is no “second best” or excuse for releasing a product until we are satisfied with its performance. It is also important to bear in mind that the PATSCAN system brings together multiple technologies, some of which have never before been configured for this type of application. While we had hoped to have the product development farther along by now, we are pleased with the advances made to-date and strongly believe our ongoing updates will deliver the performance characteristics required for the system’s intended commercial application. We have assembled an extraordinary team – from research and development to sales and marketing – that is at the top of its game and motivated to defeat the scourge of random shootings and their impact on our global society.
Can you summarize what this means, please?
Thanks!
"suffer content" That's what you get if you are invested in CCTC!
Khiron Receives INVIMA Approval to Commercialize CBD Products for Colombian Domestic Sale and Export
First Fully Licensed Company in Colombia to Receive INVIMA Approval
Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that The Colombia National Food and Drug Surveillance Institute ("INVIMA"), a level four World Health Organization ("WHO") agency, has granted Khiron authorization for the production, sale and export of four cannabidiol ("CBD") based products. This development positions Khiron as the first fully licensed medical cannabis company to receive an approval from INVIMA for cannabinoid-based products, and further solidifies the Company's first mover advantage in Colombia and Latin America.
The CBD based products approved by INVIMA will form part of Khiron's wellness business unit and will be specifically branded for consumers seeking innovative and premium products from natural sources. The Company's wellness business offers attractive margins and is focused on addressing the skin care needs of individuals. The Colombian domestic market potential for these products is currently estimated at $530 million annually. The market has grown at 6% annually over the last five years. (Source: Euromonitor International)
Khiron has completed the formulation work for these products and anticipates the products will be available for sale in the fourth quarter of 2018. In addition, due to INVIMA's status as a level four WHO agency, Khiron anticipates being able to expedite the product approval process for countries outside Colombia. INVIMA has the same level of WHO status as Canada and the United States.
Management Commentary
"At Khiron, we are focused on bringing the benefits of medical cannabis to patients and consumers across several market verticals. Our cosmetics brand will complement our medical product offerings and generate further access to various distribution channels, which broadens the addressable market potential for Khiron's product portfolio. Khiron continues to focus on finalizing distribution agreements within Colombia and abroad for these recently approved products and developing new product offerings for INVIMA approval. I would like to thank all members of our team as well as external stakeholders involved in achieving this important milestone," commented Andrés Galofre, VP, Marketing and Sales at Khiron.
"Khiron continues to solidify its first mover advantage and has again set the pace of corporate development by securing the first approvals from INVIMA of any fully licensed cannabis company in Colombia. As one of the first companies to be fully licensed, the first to list on a global stock exchange, and now the first with INVIMA approvals in Colombia, we believe we will continue to demonstrate the effectiveness of our team in achieving significant milestones, and the viability of our business model in addressing market needs," commented Alvaro Torres, President and CEO of Khiron.
About INVIMA
The Colombia National Food and Drug Surveillance Institute (Instituto Nacional de Vigilancia de Medicamentos y Alimentos or INVIMA) is a regulatory authority created under the Ministry of Health. INVIMA is in charge of inspecting and supervising the marketing and manufacturing of health products, identifying and evaluating the violation of health standards or procedures, and implementing best practices and providing medical approval for the import and export of products.
About Khiron Life Sciences Corp.
Khiron is a Canadian integrated medical cannabis company with its core operations in Colombia, and is fully licenced in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron combines leading international scientific expertise, agricultural advantages, and branded product market entrance experience to address the unmet medical needs in a market of over 620 million people in Latin America.
Further information on Khiron Life Sciences can be found at www.khiron.ca.
Forward-Looking Statements
This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Filing Statement which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) to receive an Investor Presentation.
Insurance companies may even be promoting PatScan soon!
SanFran court rules for shipping dusty coal:
https://www.cbsnews.com/news/oakland-california-ban-on-coal-shipments-judge-scraps/
Ours would alleviate such concerns!
Awesome, guy!
Hi guys! Very interesting that you have connects with Eldad. Could you share what kind of info he has shared with you?
Thanks!
Absolutely; why would he waste all of his time and others money to peruse these bogus ventures?
Anyone know how much revenue that number of transactions represents?
Sounds like things are moving forward smartly without Ed. Encouraging!
What are their plans for becoming current on financials?
Wow; wish I had known Jared H. was in on this when I bought. I was in on Enzyme too. Birds of a feather!
More great news from China:
http://www.xinhuanet.com/english/2018-05/08/c_137162370.htm
This could represent more sales than the US. They are partnering with Chinese medical groups and pioneering western medicine integration with Chinese. This will lend much credibility and acceptance of our technology!
Sounds like we have a strong support team in the making. Hopefully they will be able to carry on without Ed's input soon.